Matter of Jarvis

433 N.W.2d 120, 1988 Minn. App. LEXIS 1216, 1988 WL 130866
CourtCourt of Appeals of Minnesota
DecidedDecember 13, 1988
DocketC8-88-1785
StatusPublished
Cited by2 cases

This text of 433 N.W.2d 120 (Matter of Jarvis) is published on Counsel Stack Legal Research, covering Court of Appeals of Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Matter of Jarvis, 433 N.W.2d 120, 1988 Minn. App. LEXIS 1216, 1988 WL 130866 (Mich. Ct. App. 1988).

Opinion

OPINION

HUSPENI, Judge.

The Medical Director of the Minnesota Security Hospital petitioned for authorization to administer neuroleptic medications to Homer Jarvis, who has not consented to such treatment. Jarvis has been committed as a mentally ill and dangerous person since 1977. The trial court appointed counsel and a guardian ad litem for Jarvis. At the hearing on the petition, Jarvis sought appointment of two examiners. His motion was denied. By order on July 15,1988, the trial court approved the administration of medications. We reverse and remand for a new hearing.

FACTS

Jarvis is 54 years old. He was committed as a mentally ill and dangerous person in 1977, after he shot and killed his sister. He has been diagnosed as suffering from a paranoid disorder or from schizophrenia, paranoid type. (The chief distinguishing feature is the presence of hallucinations with schizophrenia.) Jarvis has steadfastly refused all treatment efforts and denies his mental illness. His previous challenges to forced medication resulted in a supreme court decision establishing procedures to be followed in non-emergency situations where a committed patient refuses neuro-leptic medications. Jarvis v. Levine, 418 N.W.2d 139 (Minn.1988).

Jarvis has become increasingly violent over the past year. He has attacked patients and staff at the security hospital, sometimes causing serious physical injury. He is frequently verbally abusive and attempts to provoke others. He has been placed in locked seclusion, where his condition is not expected to improve. He is not considered competent to make decisions concerning his own treatment.

The treatment review panel (a multi-disci-plinary group of professionals not directly involved in treating Jarvis, which reviews patient treatment issues) has approved the use of neuroleptic medication for Jarvis four times in the past year. Alternative therapies have been tried, but continue to be unsuccessful. In June 1988, the Medical Director of the Minnesota Security Hospital petitioned the trial court for an order authorizing forcible administration of medications.

By order on June 30, the trial court appointed an attorney (who had not previously represented Jarvis) to represent Jarvis at the hearing on the petition, but Jarvis refused to speak with his counsel or permit him to review his medical records. Two days before the scheduled hearing, counsel had still not been allowed to review the medical records to prepare. The court issued an additional order affording counsel access to the records on the eve of trial.

A guardian ad litem was also appointed, and he interviewed Jarvis, reviewed the medical records, and filed a report in support of the application for authorization of neuroleptic medications.

Jarvis refused to attend the adversary hearing on the petition on July 15, but was represented by his appointed counsel at that hearing. Psychiatrist Charles Van Valkenburg, who has treated Jarvis since January 1988, testified as to the serious deterioration in his patient’s condition. Pri- or trials of medication have produced sig *122 nificant improvement and Dr. Van Valken-burg testified that the anticipated benefits of neuroleptic medications clearly outweigh the risks.

At the close of the testimony Jarvis’ counsel moved the trial court to appoint a “second examiner” to diagnose his client’s mental illness and an additional doctor of pharmacology to offer an opinion on the proposed medications. Counsel relied on recent amendments to Minn.Stat. § 253B.17 in urging the court to appoint the examiners. Counsel for the medical director (the petitioner below) opposed the request, arguing there is no statutory authorization for such appointments and the request was untimely.

The trial court denied Jarvis’ motion, but indicated it might have granted the motion if made before the hearing. The trial court immediately announced its findings and approved the administration of neuroleptic medications. On appeal, Jarvis does not challenge the findings, but argues that he was entitled to appointment of a “second examiner.”

ISSUE

Did the trial court err in denying the patient’s motion for appointment of additional experts?

ANALYSIS

The Minnesota Supreme Court held that a treating facility seeking to administer neuroleptic medications without the consent of a committed person must comply with the so-called “Price procedure.” Jarvis v. Levine, 418 N.W.2d 139, 147 (Minn.1988). The reference is to Price v. Sheppard, 307 Minn. 250, 239 N.W.2d 905 (1976). There, the supreme court held that committed patients have a constitutional right to privacy and the state must justify treatment methods which constitute a substantial intrusion on the patient’s personal autonomy. Specifically, the court ruled that the state must, before performing psy-chosurgery or electroconvulsive therapy, obtain court approval for such treatment. Id. at 262-63, 239 N.W.2d at 913. If the patient refuses the treatment or is incompetent, the medical director must petition the court. Id. The court must also appoint a guardian ad litem for the patient. Id. After an adversary proceeding, the court must “determine the necessity and reasonableness of the prescribed treatment.” Id. Jarvis extended the application of this procedure to neuroleptic medications, which are involved in this case. Jarvis, 418 N.W.2d at 147.

In Price, the supreme court listed factors to be considered in balancing “the patient’s need for treatment against the intrusiveness of the prescribed treatment.” Price, 307 Minn, at 262-63, 239 N.W.2d at 913. The court should consider the extent and duration of the anticipated improvements, the risk of side effects, whether the treatment is experimental, acceptance of the treatment method in the medical community, the extent of intrusion into the patient’s body, and the patient’s competence to determine the desirability of the treatment. Id. The trial court’s findings in this case specifically enumerate these factors.

Both Price and Jarvis contemplate preliminary review of proposals for intrusive treatment at the hospital level. As the Jarvis opinion indicated, it may be very difficult to obtain court approval for proposed treatment if the treating physician is unable to obtain approval of his or her peers. “If, on the other hand, both the treatment review panel and the hospital review board approve of the proposal by the treating physician, court approval should be quickly forthcoming with little difficulty.” Jarvis, 418 N.W.2d at 149. Despite such approval within the hospital, the supreme court held the patient is also entitled to additional scrutiny of the application by the courts in an adversary hearing.

Neither the original procedures adopted in Price nor the procedures extended to neuroleptic medications in Jarvis

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Matter of Peterson
446 N.W.2d 669 (Court of Appeals of Minnesota, 1989)
In Re Steen
437 N.W.2d 101 (Court of Appeals of Minnesota, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
433 N.W.2d 120, 1988 Minn. App. LEXIS 1216, 1988 WL 130866, Counsel Stack Legal Research, https://law.counselstack.com/opinion/matter-of-jarvis-minnctapp-1988.